Wang H, Fu BB, Gale RP, Liang Y. NK-/T-cell lymphomas. Leukemia. 2021 Jun 11. [QxMD MEDLINE Link]. [Full Text].
Thida AM, Gohari P. Extranodal NK-Cell Lymphoma. StatPearls. 2021 Jan. [QxMD MEDLINE Link]. [Full Text].
Jaffe ES, Nicolae A, Pittaluga S. Peripheral T-cell and NK-cell lymphomas in the WHO classification: pearls and pitfalls. Mod Pathol. 2013 Jan. 26 Suppl 1:S71-87. [QxMD MEDLINE Link].
Borges A, Fink J, Villablanca P, Eversole R, Lufkin R. Midline destructive lesions of the sinonasal tract: simplified terminology based on histopathologic criteria. AJNR Am J Neuroradiol. 2000 Feb. 21(2):331-6. [QxMD MEDLINE Link].
Ooi GC, Chim CS, Liang R, Tsang KW, Kwong YL. Nasal T-cell/natural killer cell lymphoma: CT and MR imaging features of a new clinicopathologic entity. AJR Am J Roentgenol. 2000 Apr. 174(4):1141-5. [QxMD MEDLINE Link].
Sheahan P, Donnelly M, O'Reilly S, Murphy M. T/NK cell non-Hodgkin's lymphoma of the sinonasal tract. J Laryngol Otol. 2001 Dec. 115(12):1032-5. [QxMD MEDLINE Link].
Kim BS, Kim TY, Kim CW, et al. Therapeutic outcome of extranodal NK/T-cell lymphoma initially treated with chemotherapy--result of chemotherapy in NK/T-cell lymphoma. Acta Oncol. 2003. 42(7):779-83. [QxMD MEDLINE Link].
Park S, Ko YH. Epstein-Barr virus-associated T/natural killer-cell lymphoproliferative disorders. J Dermatol. 2014 Jan. 41(1):29-39. [QxMD MEDLINE Link].
Kimura H, Fujiwara S. Overview of EBV-Associated T/NK-Cell Lymphoproliferative Diseases. Front Pediatr. 2018. 6:417. [QxMD MEDLINE Link]. [Full Text].
Sangueza-Acosta M, Sandoval-Romero E. Epstein-Barr virus and skin. An Bras Dermatol. 2018 Nov/Dec. 93 (6):786-99. [QxMD MEDLINE Link]. [Full Text].
Aozasa K, Zaki MA. Epidemiology and pathogenesis of nasal NK/T-cell lymphoma: a mini-review. ScientificWorldJournal. 2011 Feb 14. 11:422-8. [QxMD MEDLINE Link].
Swerdlow E, Campo E, Harris NE, et al. IARC, Lyon. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue. 4th. 2008.
Pena C, Russo M, Martinez V, Cabrera ME. Extranodal lymphomas in the public health system in Chile: analysis of 1251 patients from the National Adult Cancer Program. Hematol Oncol. 2018 Aug 16. [QxMD MEDLINE Link].
Khariwala SS, Litman DA, McQuone SJ, Hess JL, Thaler ER. Quiz case 2. Natural killer (NK) cell/peripheral T-cell lymphoma. Arch Otolaryngol Head Neck Surg. 2000 Nov. 126(11):1391, 1393. [QxMD MEDLINE Link].
Kommalapati A, Tella SH, Ganti AK, Armitage JO. Natural Killer/T-cell Neoplasms: Analysis of Incidence, Patient Characteristics, and Survival Outcomes in the United States. Clin Lymphoma Myeloma Leuk. 2018 May 4. [QxMD MEDLINE Link].
de Arruda JAA, Schuch LF, Conte Neto N, et al. Oral and oropharyngeal lymphomas: a multi-institutional collaborative study. J Oral Pathol Med. 2021 Jun 6. [QxMD MEDLINE Link].
Suzuki R, Suzumiya J, Yamaguchi M, Nakamura S, Kameoka J, Kojima H, et al. Prognostic factors for mature natural killer (NK) cell neoplasms: aggressive NK cell leukemia and extranodal NK cell lymphoma, nasal type. Ann Oncol. 2010 May. 21(5):1032-40. [QxMD MEDLINE Link].
Su YJ, Wang PN, Chang H, et al. Extranodal NK/T-cell lymphoma, nasal type: clinical features, outcome, and prognostic factors in 101 cases. Eur J Haematol. 2018 Sep. 101 (3):379-88. [QxMD MEDLINE Link]. [Full Text].
Zhang H, Li ZL, Ye SB, et al. Myeloid-derived suppressor cells inhibit T cell proliferation in human extranodal NK/T cell lymphoma: a novel prognostic indicator. Cancer Immunol Immunother. 2015 Oct 23. [QxMD MEDLINE Link]. [Full Text].
Chen Z, Guan P, Shan T, et al. CD30 expression and survival in extranodal NK/T-cell lymphoma: a systematic review and meta-analysis. Oncotarget. 2018 Mar 27. 9 (23):16547-56. [QxMD MEDLINE Link]. [Full Text].
Wang ZY, Liu QF, Wang H, Jin J, Wang WH, Wang SL, et al. Clinical implications of plasma Epstein-Barr virus DNA in early-stage extranodal nasal-type NK/T-cell lymphoma patients receiving primary radiotherapy. Blood. 2012 Jul 23. [QxMD MEDLINE Link].
Liu ZL, Bi XW, Liu PP, Lei DX, Jiang WQ, Xia Y. The Clinical Utility of Circulating Epstein-Barr Virus DNA Concentrations in NK/T-Cell Lymphoma: A Meta-Analysis. Dis Markers. 2018. 2018:1961058. [QxMD MEDLINE Link]. [Full Text].
[Guideline] Vega F, Amador C, Chadburn A, et al. American Registry of Pathology Expert Opinions: Recommendations for the diagnostic workup of mature T cell neoplasms. Ann Diagn Pathol. 2020 Dec. 49:151623. [QxMD MEDLINE Link]. [Full Text].
Paik YS, Liess BD, Scheidt TD, Ingram EA, Zitsch RP 3rd. Extranodal nasal-type natural killer/T-cell lymphoma masquerading as recalcitrant sinusitis. Head Neck. 2009 Apr 9. [QxMD MEDLINE Link].
Chim CS, Ma SY, Au WY, et al. Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index. Blood. 2004 Jan 1. 103(1):216-21. [QxMD MEDLINE Link].
Davison SP, Habermann TM, Strickler JG, DeRemee RA, Earle JD, McDonald TJ. Nasal and nasopharyngeal angiocentric T-cell lymphomas. Laryngoscope. 1996 Feb. 106(2 Pt 1):139-43. [QxMD MEDLINE Link].
Jaffe ES. Classification of natural killer (NK) cell and NK-like T-cell malignancies. Blood. 1996 Feb 15. 87(4):1207-10. [QxMD MEDLINE Link].
Rodrigo JP, Suarez C, Rinaldo A, et al. Idiopathic midline destructive disease: fact or fiction. Oral Oncol. 2005 Apr. 41(4):340-8. [QxMD MEDLINE Link].
Cuadra-Garcia I, Proulx GM, Wu CL, et al. Sinonasal lymphoma: a clinicopathologic analysis of 58 cases from the Massachusetts General Hospital. Am J Surg Pathol. 1999 Nov. 23(11):1356-69. [QxMD MEDLINE Link].
Shimizu I, Hamano Y, Sato S, Takeda W, Kirihara T, Sato K, et al. Neurolymphomatosis in a Patient with Extranodal NK/T-cell Lymphoma, Nasal-type: A Case Report and Literature Review. Intern Med. 2014. 53(5):471-5. [QxMD MEDLINE Link].
Luther N, Greenfield JP, Chadburn A, Schwartz TH. Intracranial nasal natural killer/T-cell lymphoma: immunopathologically-confirmed case and review of literature. J Neurooncol. 2005 Nov. 75(2):185-8. [QxMD MEDLINE Link].
Suzuki R. NK/T-Cell Lymphomas: Pathobiology, Prognosis and Treatment Paradigm. Curr Oncol Rep. 2012 Oct. 14(5):395-402. [QxMD MEDLINE Link].
Tse E, Kwong YL. Practical management of natural killer/T-cell lymphoma. Curr Opin Oncol. 2012 Sep. 24(5):480-6. [QxMD MEDLINE Link].
Kwong YL, Kim WS, Lim ST, et al. SMILE for natural killer (NK)/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group. Blood. 2012 Aug 23. [QxMD MEDLINE Link].
Kim SJ, Yoon SE, Kim WS. Treatment of localized extranodal NK/T cell lymphoma, nasal type: a systematic review. J Hematol Oncol. 2018 Dec 20. 11 (1):140. [QxMD MEDLINE Link]. [Full Text].
Takahara M, Nagato T, Kishibe K, et al. Novel treatment for early-stage nasal natural killer/T-cell lymphoma: intra-maxillary arterial infusion chemotherapy with concomitant radiotherapy. Hematol Oncol. 2015 Nov 13. [QxMD MEDLINE Link].
Lin HN, Liu CY, Pai JT, Chang FP, Yang CF, Yu YB. How to predict the outcome in mature T and NK cell lymphoma by currently used prognostic models?. Blood Cancer J. 2012. 2:e93. [QxMD MEDLINE Link].
Isobe Y, Aritaka N, Setoguchi Y, Ito Y, Kimura H, Hamano Y, et al. T/NK cell type chronic active Epstein-Barr virus disease in adults: an underlying condition for Epstein-Barr virus-associated T/NK-cell lymphoma. J Clin Pathol. 2012 Mar. 65(3):278-82. [QxMD MEDLINE Link].